Synpromics announces the appointment of Sarah Haecker Meeks, PhD to the position of Vice President, Business Development.
Synpromics collaborates with UCL to generate a range of synthetic gene promoters for the CNS to develop a gene therapy for Parkinson’s disease.
Synpromics have been awarded Best Emerging UK Synthetic Biotech Company at the 2017 OBN Awards for enabling safer, more effective cell and gene medicines.
Synpromics will provide key muscle-selective promoter candidates for the development of new treatment options for Duchenne muscular dystrophy (DMD).
The new custom-built centre based at the University of Edinburgh’s allows us to meet increasing global demand for its cutting-edge gene control technology.